Oscar from Sweden

Registered at the short selling broker Skilling, 4 minutes ago.

» Try Skilling you too
69% of retail CFD accounts lose money.
Don't show again

Sanofi (SNY) stock information

Sanofi

24h Change

-0.30 %

SNY

Live rate: Market closed

Stock data per Friday 22 May, 2020

SNY
NASDAQ
47.44
47.36
47.30
-0.14 (-0.30%)
US Market is closed

Live Stock price in graph for Sanofi (SNY)

Data updated continously for SNY, showing up to the 500 most recent 100 data points

  • Latest Volume

    1,486,764 (-14.57 %)

  • Volume prev. day

    1,740,305

  • Avg. daily volume

    1,992,290

  • Market cap

    118,667,235,097

  • P/E ratio

    36.47

  • Today high

    47.72

  • Today low

    47.16

  • 52 week high

    51.84

  • 52 week low

    37.62

  • YTD Change

    n/a

 

Latest news about Sanofi

Below you can find the most recent news posts about Sanofi, primarily from US and UK based news sources.

Sanofi : to Sell Equity Investment in Regeneron | MarketScreener

Monday, 25 May 2020, 17:35:02
By Kim Richters Sanofi SA said Monday that it plans to sell its equity investment in Regeneron Pharmaceuticals Inc. via a registered public offering and a related share repurchase by… | May 25, 2020
— MarketScreener


Oxford University Coronavirus Vaccine Trial Chance Of Success Cut From 80% To Only 50%

Sunday, 24 May 2020, 22:01:00
Oxford University Coronavirus Vaccine Trial Chance Of Success Cut From 80% To Only 50% Tyler Durden Sun, 05/24/2020 – 18:01 Following the disappointing late Friday publication of a pivotal study by the New England Journal of Medicine , according to which Gilead’s Remdeisivir presented no marked benefit for those Coronavirus patients who were healthier and didn’t need oxygen or those who were sicker, requiring a ventilator or a heart-lung bypass machine , and that the only statistically significant improvement was observed in patients on supplemental oxygen, while also concluding that ” given high mortality despite the use of remdesivir, it is clear that treatment with an antiviral drug alone is not likely to be sufficient”, overnight there was more bad news, this time from the world of potential coronavirus vaccines, after the Telegraph reported that the Oxford University team in charge of developing a vaccine said a recent decline in the infection rate will make it increasingly difficult to prove whether it’s been successful. “It’s a race against the virus disappearing, and against time,” Professor Adrian Hill, director of the university’s Jenner Institute, told the newspaper. “We said earlier in the year that there was an 80% chance of developing an effective vaccine by September.
— Zero Hedge


The untold story of Moderna as the biotech’s coronavirus vaccine faces a test that could make it one of the most consequential startups of all time (MRNA)

Saturday, 23 May 2020, 11:45:00
The biotech Moderna has skyrocketed to global prominence, leading the world’s race for a coronavirus vaccine. The Cambridge, Massachusetts-based biotech was founded in 2010 with the ambitious goal to develop a new type of medicine. While its platform remains unproven, it is now being tested under the brightest possible spotlight of a pandemic. Here’s the inside story of Moderna’s rise, from an offshoot of stem cell research to routinely shattering funding records on its way to biotech’s top ranks. The biotech has spent a decade working to meet this moment, and investors have sent its stock soaring to a valuation of almost $30 billion. The next few months will be a defining period for the future of Moderna. Visit Business Insider’s homepage for more stories . In its short corporate history, Moderna has grown accustomed to breaking records. A $450 million funding round in 2015 was a record for the biotech industry. Moderna raised even more the next year. And its 2018 initial public offering was the largest ever for a biotech .
— Business Insider


Outlook on the Global Diabetes Disposable Insulin Delivery Pen Industry to 2026 – Major Players Analysed are Novo Nordisk, Eli Lilly & Sanofi Among Others – ResearchAndMarkets.com

Friday, 22 May 2020, 11:42:00
DUBLIN–(BUSINESS WIRE)–The “Worldwide Diabetes Disposable Insulin Delivery Pen Market Prospect, Share, Development, Growth & Demand Forecast to 2026” report has been added to ResearchAndMarkets.com’s offering. The Worldwide Diabetes Disposable Insulin Delivery Pen Market size is anticipated to exceed USD 14 billion by 2026. The objective of this market research report is to provide a comprehensive analysis of the fast-evolving, high-growth worldwide diabetes disposable insulin delivery pe
— Business Wire


Dr. Fauci says he’s ‘cautiously optimistic’ about COVID-19 vaccine trials

Friday, 22 May 2020, 04:25:11
On Monday, pharmaceutical company Moderna announced encouraging results from its first human trial of a potential coronavirus vaccine. “The question is: Was it immediately safe? Clearly it was,” Dr. Anthony Fauci said of the prospective vaccine. “But, importantly, it induced the kind of response that you would predict would be protective against the virus.” Several companies are working to develop a preventative solution for the coronavirus. On Thursday, the US government agreed to pay British pharmaceutical giant AstraZeneca up to $1.2 billion to secure 300 million doses of its experimental vaccine. Visit Business Insider’s homepage for more stories . Researchers developing a vaccine for the novel coronavirus have already achieved a milestone that has eluded colleagues working for decades on a vaccine for HIV, Dr. Anthony Fauci said Thursday. Earlier this week, the biotech company Moderna , which has partnered with the National Institutes of Health, announced early findings from the first phase of trials for a COVID-19 vaccine, which was tested on 45 human volunteers.
— Business Insider